目的：探讨奈达铂联合多西他赛治疗铂类敏感型复发的妇科恶性肿瘤的近期疗效和安全性。方法回顾性分析39例具有可测量病灶的铂类敏感型复发的妇科恶性肿瘤患者，采用奈达铂联合多西他赛两药联合方案治疗，奈达铂70～80 mg/m2，第1天静脉滴注，多西他赛70～75 mg/m2，第1天静脉滴注，3周重复，所有患者均完成4～6个周期化疗。采用实体肿瘤治疗疗效评估标准（RECIST）进行疗效评估，不良反应依据 WHO 抗癌药物毒性表现及分级标准进行评价。结果39例患者中…完全缓解8例、部分缓解19例，治疗总有效率为69.23%。患者中…位无进展生存时间为8.2个月。主要不良反应为白细胞降低、血小板降低、血红蛋白降低、恶心、呕吐、腹泻等…，经对症治疗后均缓解或消失，未出现不可控制感染或并发多器官功能衰竭而导致死亡。结论奈达铂联合多西他赛在铂类敏感型复发的妇科恶性肿瘤的治疗中…疗效确切，严重不良反应发生率较低，可以作为铂类敏感型复发的妇科恶性肿瘤临床治疗的一种新选择。%Objective To study the Nedaplatin platinum joint Docetaxel in the treatment of gynecological malignant tumor of the platinum sensitive recurrence of recent efficacy and safety. Methods A retrospective analysis of 39 cases with measurable lesions of platinum sensitive patients with gynecological malignant tumor recurrence, adopt Nedaplatin oxaliplatin two drugs combination therapy, Nedaplatin platinum 70~80 mg/m2, 1 days intravenous drip, Docetaxel 70~75 mg/m2, 1 days intravenous drip, all patients were complete 4~6 cycles of chemotherapy. Using solid tumor treatment response evaluation criteria in solid tumors (RECIST) to evaluate curative effect, adverse reaction according to the WHO cancer drug toxicity and classification standard for evaluation of performance. Results 39 patients in complete remission, 8 cases, partial in 19 cases, the total effective rate was 69.23%. Patients with median progression-free survival time was 8.2 months. Main adverse reactions of low white blood cells, platelets, and lower hemoglobin, nausea, vomiting, diarrhea, ease or disappeared after symptomatic treatment, not present an infection control or complicated with multiple organ failure and death. Conclusion Nedaplatin platinum joint Docetaxel in platinum sensitive in the treatment of recurrent gynecologic malignant tumor curative effect, lower incidence of serious adverse reactions, can be used as a platinum sensitive recurrent gynecologic malignant tumor a new choice for clinical treatment.
展开▼
